Ricevi le ultime notizie sulle azioni Evolus con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di EOLS

Ultime notizie per

EVOLUS INC

Evolus

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Evolus Inc

Press Releases

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product

Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp

Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer

Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch

Evolus to Report Third Quarter Financial Results on November 5, 2025

Evolus to Participate in 2025 Stifel Healthcare Conference

Evolus Reports Third Quarter 2025 Financial Results

EOLS

Aurora Cannabis

Aclaris Therapeutics, Inc. - Common Stock

Aclaris Therapeutics

Alumis

Alto Neuroscience

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Arvinas

Atea Pharmaceuticals, Inc. - common stock

Atea Pharmaceuticals

Bioage Labs

Canopy Growth Corporation - Common Shares

Canopy Growth

Contineum Therapeutics, Inc. - Common stock

Contineum Therapeutics

Cybin

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics

High Tide

LB Pharmaceuticals

LENZ Therapeutics

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics

Omeros

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Comments

Evolus Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO